Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer

被引：34
|
作者：
Mao, C. [1 ]
Liao, R-Y [1 ]
Chen, Q. [1 ]
机构：
[1] So Med Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, Guangzhou, Guangdong, Peoples R China
来源：
BRITISH JOURNAL OF CANCER | 2010年 / 102卷 / 05期
关键词：
D O I：
10.1038/sj.bjc.6605575
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：940 / 940
页数：1
相关论文
共 50 条
  • [31] Mechanisms of resistance to EGFR-targeted drugs: lung cancer
    Morgillo, Floriana
    Della Corte, Carminia Maria
    Fasano, Morena
    Ciardiello, Fortunato
    ESMO OPEN, 2016, 1 (03)
  • [32] The quest to overcome resistance to EGFR-targeted therapies in cancer
    Curtis R Chong
    Pasi A Jänne
    Nature Medicine, 2013, 19 : 1389 - 1400
  • [33] Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer (vol 5, pg 19, 2010)
    Sartore-Bianchi, Andrea
    Bencardino, Katia
    Di Nicolantonio, Federica
    Pozzi, Federico
    Funaioli, Chiara
    Gambi, Valentina
    Arena, Sabrina
    Martini, Miriam
    Lamba, Simona
    Cassingena, Andrea
    Schiavo, Roberta
    Bardelli, Alberto
    Siena, Salvatore
    TARGETED ONCOLOGY, 2012, 7 (04) : 267 - 267
  • [34] Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer
    Li, Chunpu
    Cai, Gang
    Song, Daqian
    Gao, Ruixuan
    Teng, Peng
    Zhou, LiHong
    Ji, Qing
    Sui, Hua
    Cai, Jianfeng
    Li, Qi
    Wang, Yan
    BIOMATERIALS SCIENCE, 2019, 7 (09) : 3627 - 3639
  • [35] Clinical results of EGFR-targeted therapies in advanced colorectal cancer
    Maiello, Evaristo
    Gebbia, Vittorio
    Manzione, Luigi
    Giuliani, Francesco
    Morelli, Franco
    Arcara, Carlo
    Grimaldi, Antonio
    Colucci, Giuseppe
    EJC SUPPLEMENTS, 2008, 6 (14): : 64 - 69
  • [36] Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC).
    Klempner, Samuel J.
    Quintanilha, Julia C. F. C. F.
    Emmett, Matthew
    Graf, Ryon
    Schrock, Alexa Betzig
    Tukachinsky, Hanna
    Oxnard, Geoffrey R.
    Myer, Parvathi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 52 - 52
  • [37] Drug insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer
    Mano, Max
    Humblet, Yves
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 415 - 425
  • [38] Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Simonetta M. Leto
    Livio Trusolino
    Journal of Molecular Medicine, 2014, 92 : 709 - 722
  • [39] Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer
    Max Mano
    Yves Humblet
    Nature Clinical Practice Oncology, 2008, 5 : 415 - 425
  • [40] Molecular Characterization of Acquired Resistance To Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients
    Bellosillo, Beatriz
    Dahnases, Alba
    Martinez, Alejandro
    Iglesias, Mar
    Gonzalez, Irio
    Salido, Marta
    Busto, Marcos
    Sanchez, Juan
    Vidal, Joana
    Clave, Sergi
    Moragon, Ester
    Pairet, Silvia
    Bellmunt, Joaquim
    Serrano, Sergio
    Rovira, Ana
    Albanell, Joan
    Montagut, Clara
    LABORATORY INVESTIGATION, 2015, 95 : 148A - 148A
12345